Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.30 |
| ▸ | PRKACG | P22612 | 1/20 | 0.30 |
| ▸ | PRKACB | P22694 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18839050 | 1.00 | MAPK3 (0.37) | MAPK3MAPK1KCNH2NUAK1CCNE1 | |
| SCHEMBL18839049 | 1.00 | MAPK3 (0.37) | MAPK3MAPK1KCNH2NUAK1CCNE1 | |
| SCHEMBL23607768 | 0.93 | MAPK3 (0.34) | MAPK3MAPK1KCNH2NUAK1CCNE1 | |
| SCHEMBL18861932 | 0.88 | MAPK1 (0.33) | MAPK3MAPK1KCNH2NUAK1CCNE1 | |
| SCHEMBL29862468 | 0.85 | MAPK3 (0.36) | MAPK3MAPK1KCNH2NUAK1CCNE1 | |
| SCHEMBL18131290 | 0.84 | MAPK1 (0.41) | MAPK3MAPK1KCNH2NUAK1CCNE1 | |
| SCHEMBL18131287 | 0.84 | MAPK1 (0.41) | MAPK3MAPK1KCNH2NUAK1CCNE1 | |
| SCHEMBL18839063 | 0.82 | MAPK1 (0.34) | MAPK3MAPK1KCNH2NUAK1CCNE1 | |
| SCHEMBL18839061 | 0.82 | MAPK1 (0.34) | MAPK3MAPK1KCNH2NUAK1CCNE1 | |
| SCHEMBL22747778 | 0.79 | MAPK1 (0.61) | MAPK3MAPK1KCNH2NUAK1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492210-B2 | Tricyclic compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-12-09 | — | — | US | disclosed |
| CN-117486890-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117486888-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-3845538-B1 | DIHYDROIMIDAZOPYRAZINONE COMPOUND, COMPOSITION INCLUDING SAME, AND USE THEREOF | SHENZHEN TARGETRX INC (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-3845538-B1 | DIHYDROIMIDAZOPYRAZINONE COMPOUND, COMPOSITION INCLUDING SAME, AND USE THEREOF | SHENZHEN TARGETRX INC (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-113966336-B | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230046093-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF FORMULA (I) | ASTRAZENECA AB (SE) | 2023-02-16 | — | — | US | disclosed |
| US-20220315597-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-06 | — | — | US | disclosed |
| EP-3980424-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | Hutchison Medipharma Limited (CN) | 2022-04-13 | — | — | EP | disclosed |
| CN-113966336-A | Tricyclic compound and use thereof | 和记黄埔医药（上海）有限公司 | 2022-01-21 | — | — | CN | disclosed |
| US-10202391-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-02-12 | — | — | US | disclosed |
| EP-3374359-A1 | DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2018-09-19 | — | — | EP | disclosed |
| US-20180237443-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-08-23 | — | — | US | disclosed |
| US-9902731-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-02-27 | — | — | US | disclosed |
| US-9902731-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-02-27 | — | — | US | disclosed |
| US-9902731-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-02-27 | — | — | US | disclosed |
| US-20170204100-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-07-20 | — | — | US | disclosed |
| US-20170204100-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-07-20 | — | — | US | disclosed |
| US-20170204100-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-07-20 | — | — | US | disclosed |
| WO-2017080979-A1 | DIHYDROIMIDAZOPYRAZINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202391-B2 | Chemical compounds | TP53, RB1, ABCB1 | MAPK3 1067/4885MAPK1 2059/4885KCNH2 3177/4885 |
| US-20220315597-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | CYP2C8, CYP11B2, CYP3A7 | MAPK3 4130/4885MAPK1 4572/4885KCNH2 1601/4885 |
| US-20170204100-A1 | Chemical Compounds | TP53, RB1, ABCB1 | MAPK3 1067/4885MAPK1 2059/4885KCNH2 3177/4885 |
| US-20230046093-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF FORMULA (I) | CYP2F1, CYP11B1, CYP4F11 | MAPK3 1674/4885MAPK1 614/4885KCNH2 2527/4885 |
| US-20180237443-A1 | Chemical Compounds | TP53, RB1, ABCB1 | MAPK3 1067/4885MAPK1 2059/4885KCNH2 3177/4885 |
| US-12492210-B2 | Tricyclic compounds and their use | CYP2C8, CYP11B2, CYP3A7 | MAPK3 4130/4885MAPK1 4572/4885KCNH2 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.